3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Exanthema
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Fluorouracil
11
Leucovorin
10
Oxaliplatin
9
Bevacizumab
6
Irinotecan
5
Capecitabine
3
regorafenib
2
aflibercept
2
Folfox protocol
2
Exercise
2
Chemotherapy, Adjuvant
2
Cetuximab
2
Biopsy
2
Atorvastatin
2
tucatinib
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
sulindac sulfone
1
sargramostim
1
retrovector encoding mutant anti-cyclin G1
1
poly ICLC
1
pidilizumab
1
pembrolizumab
1
p53 peptide 264-272, human
1
nilotinib
1
monalizumab
1
lonafarnib
1
irofulven
1
infigratinib
1
grp protein, Drosophila
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Colonic Neoplasms
×
Doxycycline
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn